Search research articles
Contact Us
Filters
Showing results (1-10 of 42) with videos related to
Page
of 5
Sort By:
Gut
|
March 10, 2017
What if Prometheus had steatosis? Potential use of FGF19 to promote regeneration of the fatty liver
Philip M Brown, Yaron Rotman
Current Pharmaceutical Design
|
March 12, 2015
Rheumatoid arthritis: an evolutionary force in biologics
Philip M Brown, John D Isaacs
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
November 19, 2002
Lack of pharmacokinetic interactions between argatroban and warfarin
Philip M Brown, Marcie J Hursting
Clinical Medicine (London, England)
|
December 4, 2014
Rheumatoid arthritis: from palliation to remission in two decades
Philip M Brown, John D Isaacs
Hepatology (Baltimore, Md.)
|
November 24, 2019
REPLY
Yanling Ma, Philip M Brown, Yaron Rotman
Calcified Tissue International
|
October 6, 2011
Absence of glutamine supplementation prevents differentiation of murine calvarial osteoblasts to a mineralizing phenotype
Philip M Brown, James D Hutchison, Julie C Crockett
Critical Care Medicine
|
April 9, 2004
Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy
Marian P LaMonte, Philip M Brown, Marcie J Hursting
The Clinical Teacher
|
January 10, 2012
A novel 3D stereoscopic anatomy tutorial
Philip M Brown, Neil M Hamilton, Alan R Denison
Expert Review of Cardiovascular Therapy
|
February 23, 2005
Alternative parenteral anticoagulation with argatroban, a direct thrombin inhibitor
Marian P LaMonte, Philip M Brown, Marcie J Hursting
Nature Reviews. Rheumatology
|
November 5, 2016
Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers
Philip M Brown, Arthur G Pratt, John D Isaacs
Page
of 5
Search research articles
Search
Showing results (1-10 of 42) with videos related to
Sort By:
Page
of 5
Gut
|
March 10, 2017
What if Prometheus had steatosis? Potential use of FGF19 to promote regeneration of the fatty liver
Philip M Brown, Yaron Rotman
Current Pharmaceutical Design
|
March 12, 2015
Rheumatoid arthritis: an evolutionary force in biologics
Philip M Brown, John D Isaacs
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
November 19, 2002
Lack of pharmacokinetic interactions between argatroban and warfarin
Philip M Brown, Marcie J Hursting
Clinical Medicine (London, England)
|
December 4, 2014
Rheumatoid arthritis: from palliation to remission in two decades
Philip M Brown, John D Isaacs
Hepatology (Baltimore, Md.)
|
November 24, 2019
REPLY
Yanling Ma, Philip M Brown, Yaron Rotman
Calcified Tissue International
|
October 6, 2011
Absence of glutamine supplementation prevents differentiation of murine calvarial osteoblasts to a mineralizing phenotype
Philip M Brown, James D Hutchison, Julie C Crockett
Critical Care Medicine
|
April 9, 2004
Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy
Marian P LaMonte, Philip M Brown, Marcie J Hursting
The Clinical Teacher
|
January 10, 2012
A novel 3D stereoscopic anatomy tutorial
Philip M Brown, Neil M Hamilton, Alan R Denison
Expert Review of Cardiovascular Therapy
|
February 23, 2005
Alternative parenteral anticoagulation with argatroban, a direct thrombin inhibitor
Marian P LaMonte, Philip M Brown, Marcie J Hursting
Nature Reviews. Rheumatology
|
November 5, 2016
Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers
Philip M Brown, Arthur G Pratt, John D Isaacs
Page
of 5